DE69531342D1 - Avidin-biotin immunokonjugate - Google Patents

Avidin-biotin immunokonjugate

Info

Publication number
DE69531342D1
DE69531342D1 DE69531342T DE69531342T DE69531342D1 DE 69531342 D1 DE69531342 D1 DE 69531342D1 DE 69531342 T DE69531342 T DE 69531342T DE 69531342 T DE69531342 T DE 69531342T DE 69531342 D1 DE69531342 D1 DE 69531342D1
Authority
DE
Germany
Prior art keywords
biotin
viral vector
cell
immunoconjugate
avidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69531342T
Other languages
English (en)
Inventor
Michael G Rosenblum
Nicholas J Donato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Development Foundation
Original Assignee
Research Development Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Development Foundation filed Critical Research Development Foundation
Application granted granted Critical
Publication of DE69531342D1 publication Critical patent/DE69531342D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69531342T 1994-02-07 1995-02-06 Avidin-biotin immunokonjugate Expired - Lifetime DE69531342D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19265594A 1994-02-07 1994-02-07
PCT/US1995/001161 WO1995021195A1 (en) 1994-02-07 1995-02-06 Non-viral vector

Publications (1)

Publication Number Publication Date
DE69531342D1 true DE69531342D1 (de) 2003-08-28

Family

ID=22710534

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69531342T Expired - Lifetime DE69531342D1 (de) 1994-02-07 1995-02-06 Avidin-biotin immunokonjugate

Country Status (16)

Country Link
US (1) US6214974B1 (de)
EP (1) EP0743958B1 (de)
JP (1) JP4015693B2 (de)
KR (1) KR100376390B1 (de)
CN (1) CN1200950C (de)
AT (1) ATE245662T1 (de)
AU (1) AU695564B2 (de)
CA (1) CA2182616A1 (de)
DE (1) DE69531342D1 (de)
FI (1) FI963103A (de)
IL (1) IL112372A (de)
NO (1) NO319899B1 (de)
NZ (1) NZ281763A (de)
RU (1) RU2164943C2 (de)
SA (1) SA95150519B1 (de)
WO (1) WO1995021195A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE62496B1 (en) * 1990-04-19 1995-02-08 Res Dev Foundation Antibody conjugates for treatment of neoplastic disease
ATE229193T1 (de) * 1994-02-08 2002-12-15 Australia Res Lab Mehrfarbenbilderzeugungsgerät mit flüssigentwicklung
DE19605279A1 (de) * 1996-02-13 1997-08-14 Hoechst Ag Zielzellspezifische Vektoren für die Einschleusung von Genen in Zellen, Arzneimittel enthaltend derartige Vektoren und deren Verwendung
CA2338000C (en) * 1998-07-17 2009-12-15 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Water-soluble 4-thio-maleimido derivatives and methods for their production
FR2793414B1 (fr) * 1999-05-10 2003-05-23 Centre Nat Rech Scient Conjugue acide nucleique-anticorps pour delivrer un acide nucleique etranger dans les cellules
GB9930533D0 (en) * 1999-12-23 2000-02-16 Mitsubishi Tokyo Pharm Inc Nucleic acid delivery
ZA200305980B (en) * 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
US7265208B2 (en) * 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
WO2002100892A1 (en) * 2001-05-29 2002-12-19 Regents Of The University Of Michigan Systems and methods for the analysis of proteins
ATE440869T1 (de) * 2001-06-20 2009-09-15 Fibron Ltd Fgfr3 blockierende antikírper, verfahren zum screening darauf und verwendungen davon
DK1399484T3 (da) * 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US7101977B2 (en) * 2001-07-17 2006-09-05 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
WO2003082346A1 (fr) * 2002-04-02 2003-10-09 'asgl-Farmatsevticheskie Innovatsii', Zakrytoe Aktsionernoe Obschestvo Proteine chimerique recombinante servant a l'administration ciblee d'adn dans des cellules cibles eucaryotes
WO2003105761A2 (en) * 2002-06-12 2003-12-24 Research Development Foundation Immunotoxin as a therapeutic agent and uses thereof
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
EP2366718A3 (de) * 2002-06-28 2012-05-02 Domantis Limited Ligand
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
EP1578801A2 (de) * 2002-12-27 2005-09-28 Domantis Limited Dual-spezifischer einzeldomäne-antikörper welcher spezifisch ist für einen liganden und dessen rezeptor
WO2005074417A2 (en) * 2003-09-03 2005-08-18 Salk Institute For Biological Studies Multiple antigen detection assays and reagents
CN101104856B (zh) * 2003-11-18 2010-11-10 中国医学科学院基础医学研究所 一个系列的非病毒载体及包含其的药物组合物
WO2006083961A2 (en) * 2005-02-01 2006-08-10 Research Development Foundation Blys fusion proteins for targeting blys receptor and methods for treatment of b-cell proliferative disorders
EP1957536A2 (de) * 2005-12-01 2008-08-20 Domantis Limited Nichtkompetitive domänenantikörperformate, die an den interleukin-1-rezeptor vom typ 1 binden
US8877186B2 (en) * 2007-06-06 2014-11-04 Domantis Limited Polypeptides, antibody variable domains and antagonists
EP2646470B1 (de) 2010-11-30 2017-03-01 F. Hoffmann-La Roche AG Antikörper gegen transferin rezeptor mit niedriger affinität und ihre verwendungen zur überwindung der bluthirnschranke
US9623117B2 (en) * 2011-04-04 2017-04-18 Wisconsin Alumni Research Foundation Method for selective targeting and entry of bacterial toxins to cells
EP3912619A1 (de) 2011-05-11 2021-11-24 Children's Medical Center Corporation Modifiziertes biotin-bindendes protein, fusionsproteine davon und anwendungen
CA2900008A1 (en) 2013-02-07 2014-08-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
CN107427550B (zh) 2015-01-16 2021-10-08 希望之城 细胞穿透抗体
CN110730670A (zh) 2017-03-28 2020-01-24 儿童医疗中心有限公司 基于多抗原提呈系统(maps)的金黄色葡萄球菌疫苗、免疫原性组合物以及它们的用途
TW201925222A (zh) 2017-06-23 2019-07-01 美商醫院疫苗公司 免疫原性組成物
CN112969474A (zh) 2018-09-12 2021-06-15 艾芬尼维克斯公司 多价肺炎球菌疫苗
EP4203989A2 (de) 2020-09-03 2023-07-05 Rampart Bioscience, Inc. Lösliche alkalische phosphatasekonstrukte und expressionsvektoren mit einem polynukleotid zur codierung löslicher alkalischer phosphatasekonstrukte

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4545985A (en) * 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US5525338A (en) * 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
US5026785A (en) * 1989-05-12 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Avidin and streptavidin modified water-soluble polymers such as polyacrylamide, and the use thereof in the construction of soluble multivalent macromolecular conjugates
IT1245748B (it) * 1990-12-21 1994-10-14 Mini Ricerca Scient Tecnolog Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego
ZA932522B (en) * 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
ZA932523B (en) * 1992-04-10 1994-10-08 Res Dev Foundation Immunotoxins directed against cd33 related surface antigens
ATE210464T1 (de) * 1992-06-09 2001-12-15 Neorx Corp BIOTIN-DOTA KONJUGATE UND DEREN VERWENDUNG IN ßPRETARGETINGß VERFAHREN
US5482698A (en) * 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
KR100220864B1 (ko) * 1993-05-17 1999-09-15 오트리브 데이비스 더블유 비오틴/아비딘-금속 단백질 콘쥬게이트로 병변을 검출 및 치료하기 위한 조성물
EP0733066B1 (de) * 1993-12-07 2003-11-19 NeoRx Corporation Pretargeting verfahren und mitteln

Also Published As

Publication number Publication date
NO963283D0 (no) 1996-08-06
EP0743958A1 (de) 1996-11-27
WO1995021195A1 (en) 1995-08-10
FI963103A (fi) 1996-10-01
IL112372A (en) 2001-08-26
AU1868795A (en) 1995-08-21
KR970700771A (ko) 1997-02-12
KR100376390B1 (ko) 2003-06-12
CN1143374A (zh) 1997-02-19
JPH09508792A (ja) 1997-09-09
NO963283L (no) 1996-08-06
IL112372A0 (en) 1995-03-30
CN1200950C (zh) 2005-05-11
AU695564B2 (en) 1998-08-13
FI963103A0 (fi) 1996-08-06
SA95150519B1 (ar) 2005-07-24
CA2182616A1 (en) 1995-08-10
ATE245662T1 (de) 2003-08-15
US6214974B1 (en) 2001-04-10
NZ281763A (en) 2001-06-29
NO319899B1 (no) 2005-09-26
RU2164943C2 (ru) 2001-04-10
JP4015693B2 (ja) 2007-11-28
EP0743958A4 (de) 1999-07-28
EP0743958B1 (de) 2003-07-23

Similar Documents

Publication Publication Date Title
DE69531342D1 (de) Avidin-biotin immunokonjugate
ATE297762T1 (de) Peg-lhrh analog konjugate
DK1093383T3 (da) Lægemiddelafgivelsessystem omfattende et homeobox-peptid og et cytotoksisk eller antineoplastisk lægemiddel
WO1997044063A3 (en) Dha-pharmaceutical agent conjugates
ES2194114T3 (es) Formulaciones liposomicas de mitoxantrona.
AU2001255260A1 (en) Macroaggregated protein conjugates as oral genetic immunization delivery agents
AU2732597A (en) Novel pharmaceutical compositions having steroid nitrate ester derivatives useful as anti-inflammatory drugs
EA199700151A1 (ru) Композиция для чрескожного введения
IL126714A (en) Use of cells, organs or components thereof for the preparation of a pharmaceutical composition for establishing selective immune downregulation
GR3034575T3 (en) Steroid nitrite ester derivatives useful as anti-inflammatory drugs
HUP0100350A3 (en) Conjugates useful in the treatment of prostate cancer, pharmaceutical compositions comprising thereof, process for their preparation and their use
WO2003045429A3 (en) Anti-t cell immunotoxin fusion protein and its therapeutic use
IL118218A (en) Pharmaceutical compositions containing sarcodictyins
MX9803662A (es) Oligopeptidos novedosos, preparacion y uso de estos.
AU7089800A (en) 29 human cancer associated proteins
WO2000042987A8 (en) Targeted vesicular constructs for cytoprotection and treatment of h. pylori infections
AU5685300A (en) Solid preparations containing paroxetine
WO2000017366A3 (en) Pharmaceutical composition for the pre-treatment of a patient in need of drug or pro-drug
PT1150716E (pt) Composicao farmaceutica de proteinas hedgehog hidrofobicamente modificadas e sua utilizacao
EP1051966A3 (de) Kosmetische und/oder pharmazeutische Zubereitungen mit einem Gehalt an Alkyl- und/oder Alkenyloligoglykosiden, Fettsäurepartialglyceriden, Esterquats und hydroxyalkylertem Guar als Verdickungsmittel
ZA964871B (en) Conjugates of ferrites and oligonucleotides, which bond specifically to certain target structures.
CA2458872A1 (en) Human ubiquitin-conjugating enzyme
WO1998051792A8 (en) Fac molecules and uses thereof
SI0898477T1 (en) Topical administration of premafloxacin for the treatment of systemic bacterial diseases
AUPN058795A0 (en) Therapeutic conjugates 9

Legal Events

Date Code Title Description
8332 No legal effect for de